शेयरखान

#SharekhanFNA #SharekhanResearch #Q3FY22 Pharma Review- weak qtr, strng gwth in India bizz, US gwth muted while cos… https://t.co/AdYDkj4Qai #SharekhanFNA #SharekhanResearch #Q3FY22

#SharekhanFNA #SharekhanResearch retains Buy rating on #Divis (PT Rs 5620) #Q3FY22 strng qtr, rslts ahead of est; C… https://t.co/svLM1XfNwC #SharekhanFNA #SharekhanResearch #Divis #Q3FY22

#SharekhanResearch retains Positive view on #Metropolis (Upside 35%) #Q3FY22 weak qtr; focus to grow B2C biz & incr… https://t.co/4e8KPiHe03 #SharekhanResearch #Metropolis #Q3FY22

#SharekhanFNA #SharekhanResearch retains Hold on #StridesPharma (PT Rs450) #Q3FY22 was another weak qtr; near term… https://t.co/8nI3HniDms #SharekhanFNA #SharekhanResearch #StridesPharma #Q3FY22

#SharekhanResearch retains Buy rating on #Aurobindo (PT Rs 875), Weak #Q3FY22; US price erosion likely to stabilise… https://t.co/Hw1ifoJClZ #SharekhanResearch #Aurobindo #Q3FY22

#SharekhanResearch retains Buy on #Cadila (PT Rs560) #Q3FY22 was steady qtr; Strng gwth outlook for India & Emergin… https://t.co/KxwLn7pZg9 #SharekhanResearch #Cadila #Q3FY22

#SharekhanFNA #SharekhanResearch retains Buy on #LaurusLabs (PT Rs735) #Q3FY22 was a weak qtr, results missed est;… https://t.co/5FLSMtWLVJ #SharekhanFNA #SharekhanResearch #LaurusLabs #Q3FY22

#SharekhanResearch retains Buy rating on #Cipla (PT Rs 1150) #Q3FY22 was mixed qtr, results ahead of est, strng gwt… https://t.co/7w4OwWoUI3 #SharekhanResearch #Cipla #Q3FY22

#SharekhanResearch retains Buy rating on #TorrentPharma (PT Rs3540) #Q3FY22 was weak qtr, results missed est; India… https://t.co/IW0KB9nRC0 #SharekhanResearch #TorrentPharma #Q3FY22